Ravi Persaud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ravi Persaud has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andy Forreryd
SenzaGen AB, 22381 Lund, Sweden
1 shared publication - Emma Anders
SenzaGen AB, SE-22481 Lund, Sweden
1 shared publication - Henrik Johansson
SenzaGen AB, 22381 Lund, Sweden
1 shared publication - Johan Andersson
SenzaGen AB, 22381 Lund, Sweden
1 shared publication - Nakul Ruparel
Apple, Inc., Cupertino, CA 95014, USA
1 shared publication - Per Alftrén
SenzaGen AB, SE-22481 Lund, Sweden
1 shared publication
Latest Publications
- Open Access
Assessing the Skin Sensitizing Potential of Constituents and Leachables from Wearable Devices Using GARDskin and Associated Applications
Pre-clinical toxicological evaluation is an essential component of ensuring the safety and compatibility of wearable devices with biological systems. Along with the local endpoints of cytotoxicity and irritation, skin sensitization is a core toxicological endpoint. Testing wearable devices, which are often solid and composed of multiple components, presents new challenges for New Approach Methods. In the current proof-of-concept study, we propose a strategy for conducting risk assessment of the individual components and the leachables from wearable devices. The GARDskin Dose-Response assay (OECD TGP 4.106) was used to predict the skin sensitization potency of three acrylate monomers, two acrylamide monomers, and one reactive dye. The GARDskin Medical Device (ISO 10993-10:2021, Annex C) was used to classify MED-2000 extracts spiked with isobornyl acrylate. All chemicals were classified as skin sensitizers. The quantitative potency predictions correlated well with available data from defined approaches and produced near-identical potency rankings. Available human and animal reference data were too sparse and heterogenous to substantiate agreement in potency. Finally, the GARDskin Medical Device assay correctly classified the spiked extract as skin sensitizing. In conclusion, the GARDskin assay and associated applications are well adapted to address the testing requirements for wearable devices.
Open AccessAssessing the Skin Sensitizing Potential of Constituents and Leachables from Wearable Devices Using GARDskin and Associated Applications
Pre-clinical toxicological evaluation is an essential component of ensuring the safety and compatibility of wearable devices with biological systems. Along with the local endpoints of cytotoxicity and irritation, skin sensitization is a core toxicological endpoint. Testing wearable devices, which are often solid and composed of multiple components, presents new challenges for New Approach Methods. In the current proof-of-concept study, we propose a strategy for conducting risk assessment of the individual components and the leachables from wearable devices. The GARDskin Dose-Response assay (OECD TGP 4.106) was used to predict the skin sensitization potency of three acrylate monomers, two acrylamide monomers, and one reactive dye. The GARDskin Medical Device (ISO 10993-10:2021, Annex C) was used to classify MED-2000 extracts spiked with isobornyl acrylate. All chemicals were classified as skin sensitizers. The quantitative potency predictions correlated well with available data from defined approaches and produced near-identical potency rankings. Available human and animal reference data were too sparse and heterogenous to substantiate agreement in potency. Finally, the GARDskin Medical Device assay correctly classified the spiked extract as skin sensitizing. In conclusion, the GARDskin assay and associated applications are well adapted to address the testing requirements for wearable devices.